BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 16456688)

  • 21. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
    Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
    J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.
    Carlson ER; Basile JD
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):85-95. PubMed ID: 19371819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteonecrosis of the jaw in patients on bisphosphonate treatment. review of literature with contribution of a case of multiple myeloma.
    Goranova-Marinova VS; Pechalova-Petrova PF; Goranov SG
    Folia Med (Plovdiv); 2009; 51(4):53-7. PubMed ID: 20232660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
    Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients.
    Favia G; Pilolli GP; Maiorano E
    J Rheumatol; 2009 Dec; 36(12):2780-7. PubMed ID: 19884275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.
    Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S
    J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review.
    Mortensen M; Lawson W; Montazem A
    Laryngoscope; 2007 Jan; 117(1):30-4. PubMed ID: 17202926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
    Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY
    Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.
    Cafro AM; Barbarano L; Nosari AM; D'Avanzo G; Nichelatti M; Bibas M; Gaglioti D; Taroni A; Riva F; Morra E; Andriani A
    Clin Lymphoma Myeloma; 2008 Apr; 8(2):111-6. PubMed ID: 18501105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
    Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
    Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: report of 2 cases.
    Lee JJ; Cheng SJ; Wang YP; Jeng JH; Chiang CP; Kok SH
    Head Neck; 2013 Jan; 35(1):E6-10. PubMed ID: 21523843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
    Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
    J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
    Merigo E; Manfredi M; Meleti M; Guidotti R; Ripasarti A; Zanzucchi E; D'Aleo P; Corradi D; Corcione L; Sesenna E; Ferrari S; Poli T; Bonaninil M; Vescovi P
    Acta Biomed; 2006 Aug; 77(2):109-17. PubMed ID: 17172192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons.
    Yoneda T; Hagino H; Sugimoto T; Ohta H; Takahashi S; Soen S; Taguchi A; Toyosawa S; Nagata T; Urade M
    J Bone Miner Metab; 2010 Jul; 28(4):365-83. PubMed ID: 20333419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonate associated osteonecrosis of the jaw.
    Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Lentle B; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Mardini MA; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; Ste-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
    J Rheumatol; 2009 Mar; 36(3):478-90. PubMed ID: 19286860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
    Kyrgidis A; Vahtsevanos K; Koloutsos G; Andreadis C; Boukovinas I; Teleioudis Z; Patrikidou A; Triaridis S
    J Clin Oncol; 2008 Oct; 26(28):4634-8. PubMed ID: 18574158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM
    Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
    Brown JJ; Ramalingam L; Zacharin MR
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.